Drug developpment Drug developpment
Select your search
Contact us

(Unwanted) Immunogenicity

Immunogenicity Bertin Pharma

Bertin Pharma has more than two decades of experience in Immunogenicity, both in the direction to reveal a pharmacological efficacy and in the deleterious direction i.e. neutralization of the biological activity of a biologics such as therapeutical proteins better known under the term "Anti-Drug Antibody (ADA).

Our Know-How & Technologies aim to answer to the following questions...

  • what is the pharmacokinetic (PK) of a therapeutic protein?
  • are there host antibodies and the emergence of ADA against a therapeutic protein?
  • and if yes, do they modify its concentration and/or PK and/or PD?
  • what are the characteristics & concentrations of such antibodies?
  • do they neutralise drug efficacy?
  • do they cause side-effects such as allergic or anaphylactic reactions and/or autoimmune diseases?

Our expertise permits to undertake...

  • implementation of preclinical studies in the most relevant animal species (in-house or in collaboration with our partner, CERB)
  • set-up and development of specific assays in various species & biological media
  • validation studies according to ICH & EMEA guidelines and FDA note for guidance
  • experiments in GLP conditions

For this & for example, we use...

  • a patented AChE revelation technology with several advantages over other enzymes conventionally used in EIAs i.e. kinetics superiority, low background, versatility, high sensibility & precision
  • our platform dedicated to production of monoclonal & polyclonal antibodies
  • specific standard & original EIA formats
  • titration of positive samples, immunodepletion or competition assays as well as immunoblots & Surface Plasmon Resonance (SPR) assays used as confirmatory assays
  • various specific binding-, enzyme- & cell-based assays

In vitro & in vivo Predictive Immunogenicity Assays

  • in vitro: Biotherapeutic candidates or peptides corresponding to previously identified epitopes are tested in vitro using a T cell proliferation assay using peripheral blood mononuclear cells (PBMC) isolated from different blood donors (between 20 and 50) with various HLA. Then, in a second step, we can assess the processing of these biotherapeutic candidates as antigen by dendritic cells using DC-T cell coculture assays. Dendritic cells are obtained by diffentiation of human monocytes previously isolated by CD14+ cell sorting in a PBMC population.

  • in vivo: Immunogenicity is explored using mice humanized for the immune system using human CD34+ hematopoietic progenitor cells (In collaboration with Axenis).


Bertin Pharma - Drug developpment

Follow Us

Linkedin Youtube Twitter Google+

Contact us

Any project? Any challenge? We are in!
+33 (0) 139 306 260
Any questions? Contact us

Parc d’Activités du Pas du Lac
10 bis avenue Ampère
78180 Montigny le Bretonneux - France
View our other locations


Do you want to be kept updated with Bertin Pharma's latest news?

Manage my subscriptions